BICC1-FGFR2 fusion is the most common FGFR2 fusion partner in intrahepatic cholangiocarci...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR2-BICC1-CHOLANGIO |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-CIVIC SRC-FDA-CDS-2026 |
Actionability Facts
| Biomarker | BIO-FGFR2 |
|---|---|
| Variant | BICC1-FGFR2 fusion (most common partner ~30-40% of FGFR2-fusion cholangio) |
| Disease | DIS-CHOLANGIOCARCINOMA |
| ESCAT tier | IA |
| Recommended combinations | pemigatinib monotherapy, futibatinib monotherapy |
| Evidence summary | BICC1-FGFR2 fusion is the most common FGFR2 fusion partner in intrahepatic cholangiocarcinoma. Treatment is identical to gene-level FGFR2-fusion: pemigatinib (FIGHT-202) and futibatinib (FOENIX-CCA2). Fusion-partner identity does not currently modify TKI selection. |
Notes
ESCAT IA. OncoKB Level 1. Fusion-partner-specific cell maintained for completeness.
Used By
No reverse references found in the YAML corpus.